NK007 helps in mitigating paclitaxel resistance through p38MAPK activation and HK2 degradation in ovarian cancer

Area of Science:

• Pharmacology
• Oncology
• Natural Products Chemistry

Background:

• Ovarian cancer chemoresistance poses a significant clinical challenge, leading to high recurrence and mortality rates.
• Drug screening from natural products offers a promising avenue to overcome chemoresistance.
• Paclitaxel resistance is a major obstacle in treating advanced ovarian cancer.

Purpose of the Study:

• To investigate the potential of NK007, a tylophorine analog from the Asclepiadaceae family, as an agent to overcome paclitaxel resistance in ovarian cancer.
• To elucidate the molecular mechanisms underlying NK007's anti-cancer effects in paclitaxel-resistant ovarian cancer cells.

Main Methods:

• NK007 was isolated from the Asclepiadaceae family.
• Cell proliferation, migration, apoptosis, cell cycle, protein expression, and metabolic activity were assessed in A2780 and A2780 (Taxol) cells.
• Key molecular targets including p38 mitogen-activated protein kinase (p38MAPK) and hexokinase 2 (HK2) were analyzed.

Main Results:

• NK007 selectively inhibited proliferation and migration of paclitaxel-sensitive and -resistant ovarian cancer cells, independent of apoptosis.
• NK007 induced G1/S cell cycle arrest and upregulated phospho-p38MAPK expression.
• NK007 promoted hexokinase 2 (HK2) protein degradation, reducing cellular oxygen consumption and extracellular acidification rates.

Conclusions:

• NK007 effectively overcomes paclitaxel resistance in ovarian cancer by activating p38MAPK and inducing HK2 degradation.
• NK007 demonstrates potential as an alternative therapeutic agent for paclitaxel-resistant ovarian cancer.
• This study highlights the therapeutic promise of tylophorine analogs in combating drug-resistant cancers.